巨噬细胞移动抑制因子在复发性宫颈癌中的表达及其对预后的影响

Expression of macrophage migration-inhibitory factor in human recurrent cervical cancer tissues and its prognostic significance

目的:研究巨噬细胞移动抑制因子(macrophage migration-inhibitory factor,MIF)在复发性宫颈癌中的表达及其对预后的影响。方法:2007年1月至2009年12月期间收集我院确诊宫颈癌手术后复发患者87例,采用免疫组化方法检测MIF的表达情况,并对患者进行至少36个月的随访。结果:复发性宫颈癌患者MIF阳性率为75.7%(55/87)。MIF表达与宫颈癌分化程度和临床分期相关,差异有统计学意义(P<0.01);但是不同宫颈癌病理分型MIF表达差异无统计学意义(P>0.05)。复发性宫颈癌MIF阳性者近期治疗有效率为47.3%(26/55),MIF阴性者近期治疗有效率为63.6%(21/32),二者相比差异有统计学意义(P<0.05)。Kaplan-Meier生存分析结果表明MIF表达阳性组平均生存时间为28.8个月,阴性组平均生存时间为38.4个月,log-rank检验P<0.05。结论:MIF阳性可能是影响宫颈癌复发和预后的危险因素之一。

AIM：To investigate the expression of macrophage migration-inhibitory factor （MIF） in human recurrent cervical cancer tissues and its influence on prognosis. METHODS：Eight-seven cases of recurrent cervical cancer were collected from January 2007 to December 2009 and followed up for at least 36 months. The MIF expression in cervical cancer tissues was tested by immunochemistry. RESULTS：The positive rate of MIF expression in recurrent cervical cancer was 75.7% （55/87）. Compared with the patients with negative MIF expression, the patients with positive MIF expression showed worse response to antitumor therapy [47.3% （26/55） vs 63.6% （21/32）, P〈0.05] and shorter survival time （28.8 months vs 38.4 months, P〈0.05）. CONCLUSION：Positive MIF expression could be a risk factor in recurrence and prognosis of cervical cancer.